MX2015002658A - Una composicion farmaceutica para la estimulacion de la angiogenesis. - Google Patents
Una composicion farmaceutica para la estimulacion de la angiogenesis.Info
- Publication number
- MX2015002658A MX2015002658A MX2015002658A MX2015002658A MX2015002658A MX 2015002658 A MX2015002658 A MX 2015002658A MX 2015002658 A MX2015002658 A MX 2015002658A MX 2015002658 A MX2015002658 A MX 2015002658A MX 2015002658 A MX2015002658 A MX 2015002658A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- plasmid dna
- vegf165
- pcmv
- 8âoc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
Se proporciona una composición farmacéutica para la inducción de crecimiento en el tejido del vaso sanguíneo que contiene el ADN plasmático purificado que codifica un factor de crecimiento endotelial vascular (VEGF, por sus siglas en inglés) y excipientes farmacéuticamente aceptables que incluyen un crioprotector como un vehiculo y/o un estabilizar el pH en el intervalo de 7.0 a 9.0. en cantidades eficaces. Tambien se proporciona un método de almacenamiento de ADN plasmático purificado con una solución de al menos uno crioprotectores que tienen propiedades de un vehiculo y/o un estabilizador de Ph en el intervalo de pH de 7.9-9.0. La solución se liofiliza y se almacena de +2 a +8°C. El ADN superenrollado pCMV-VEGFI65 puede usarse que es producido cultivando una cepa de Escherichia coli TOP1Oau/pCMV-VEGF165. La composición farmacéutica es administrada a un humano en cantidades suficientes para proporcionar un efecto terapéutico necesario. La composición farmacéutica proporcionada del ADN plasmático pCMV-VEGF165 no cambia significativamente las propiedades de la sustancia activa cuando se almacena durante un largo tiempo a una temperatura de +2 a +8°C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012137126/10A RU2542385C2 (ru) | 2012-08-31 | 2012-08-31 | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
PCT/RU2013/000669 WO2014035289A1 (en) | 2012-08-31 | 2013-08-02 | A pharmaceutical composition for stimulation of angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015002658A true MX2015002658A (es) | 2015-09-25 |
MX360980B MX360980B (es) | 2018-11-22 |
Family
ID=50183970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002658A MX360980B (es) | 2012-08-31 | 2013-08-02 | Una composición farmacéutica para la estimulación de la angiogénesis. |
Country Status (13)
Country | Link |
---|---|
US (1) | US9616103B2 (es) |
EP (1) | EP2890777B1 (es) |
CN (1) | CN105308173B (es) |
BR (1) | BR112015002522B1 (es) |
CA (1) | CA2881799C (es) |
ES (1) | ES2621675T3 (es) |
HU (1) | HUE032520T2 (es) |
MX (1) | MX360980B (es) |
PL (1) | PL2890777T3 (es) |
RU (1) | RU2542385C2 (es) |
SI (1) | SI2890777T1 (es) |
WO (1) | WO2014035289A1 (es) |
ZA (1) | ZA201500909B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2558294C1 (ru) * | 2014-09-16 | 2015-07-27 | Общество с ограниченной ответственностью "НекстГен" | Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека |
RU2612497C2 (ru) | 2015-05-26 | 2017-03-09 | Общество с ограниченной ответственностью "НекстГен" | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
RU2694826C1 (ru) * | 2018-06-05 | 2019-07-17 | Юрий Валентинович Червяков | Способ лечения хронической ишемии нижних конечностей атеросклеротического генеза при окклюзии артерий голени |
EP3833244A4 (en) * | 2018-08-08 | 2022-08-03 | Brightspec, Inc. | LOW VOLATILITY SAMPLING METHODS AND APPARATUS |
CN110760542B (zh) * | 2019-11-18 | 2022-07-26 | 天津大学 | 一种共表达znf580和vegf165双基因的质粒及应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU742365B2 (en) * | 1997-03-14 | 2002-01-03 | Selective Genetics, Inc. | Adenoviral vectors with modified tropism |
US6627436B2 (en) * | 1997-10-31 | 2003-09-30 | Stratagene | Vector for gene expression in prokaryotic and eukaryotic systems |
AU765177B2 (en) * | 1998-03-13 | 2003-09-11 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
WO2000047235A2 (en) | 1999-02-10 | 2000-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of stimulating angiogenesis |
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7288521B2 (en) | 2000-04-06 | 2007-10-30 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
CN1351055A (zh) | 2000-10-26 | 2002-05-29 | 上海博德基因开发有限公司 | 一种新的多肽——人的血管内皮生长因子165受体(vegf-165r)10.67和编码这种多肽的多核苷酸 |
US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
CN100431611C (zh) | 2002-07-04 | 2008-11-12 | 朱静亚 | 多肽-脂质体与人血管内皮生长因子基因重组质粒复合物及用途 |
ATE474604T1 (de) | 2002-12-02 | 2010-08-15 | Anges Mg Inc | Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen |
BRPI0515553A (pt) * | 2004-09-17 | 2008-07-29 | Centelion | formulações lìquidas estáveis de dna de plasmìdeo |
RU2297848C2 (ru) * | 2005-05-11 | 2007-04-27 | Александр Веньяминович Иткес | Генно-инженерная конструкция vegf-ибмед (vegf-ibmed) |
ES2338400B1 (es) | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
US8367350B2 (en) * | 2009-04-29 | 2013-02-05 | Morehouse School Of Medicine | Compositions and methods for diagnosis, prognosis and management of malaria |
-
2012
- 2012-08-31 RU RU2012137126/10A patent/RU2542385C2/ru active
-
2013
- 2013-08-02 WO PCT/RU2013/000669 patent/WO2014035289A1/en active Application Filing
- 2013-08-02 SI SI201330595A patent/SI2890777T1/sl unknown
- 2013-08-02 ES ES13832746.5T patent/ES2621675T3/es active Active
- 2013-08-02 CN CN201380045032.7A patent/CN105308173B/zh active Active
- 2013-08-02 EP EP13832746.5A patent/EP2890777B1/en active Active
- 2013-08-02 US US14/423,532 patent/US9616103B2/en active Active
- 2013-08-02 PL PL13832746T patent/PL2890777T3/pl unknown
- 2013-08-02 HU HUE13832746A patent/HUE032520T2/en unknown
- 2013-08-02 MX MX2015002658A patent/MX360980B/es active IP Right Grant
- 2013-08-02 BR BR112015002522-6A patent/BR112015002522B1/pt active IP Right Grant
- 2013-08-02 CA CA2881799A patent/CA2881799C/en active Active
-
2015
- 2015-02-09 ZA ZA2015/00909A patent/ZA201500909B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2542385C2 (ru) | 2015-02-20 |
PL2890777T3 (pl) | 2017-07-31 |
CA2881799A1 (en) | 2014-03-06 |
HUE032520T2 (en) | 2017-10-30 |
US20150335711A1 (en) | 2015-11-26 |
EP2890777B1 (en) | 2017-01-11 |
CN105308173A (zh) | 2016-02-03 |
EP2890777A1 (en) | 2015-07-08 |
WO2014035289A1 (en) | 2014-03-06 |
ZA201500909B (en) | 2016-10-26 |
ES2621675T3 (es) | 2017-07-04 |
MX360980B (es) | 2018-11-22 |
CA2881799C (en) | 2019-10-29 |
EP2890777A4 (en) | 2015-12-16 |
BR112015002522A2 (pt) | 2017-11-07 |
BR112015002522B1 (pt) | 2022-04-05 |
WO2014035289A9 (en) | 2014-05-08 |
CN105308173B (zh) | 2020-03-17 |
SI2890777T1 (sl) | 2017-06-30 |
RU2012137126A (ru) | 2014-03-10 |
US9616103B2 (en) | 2017-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015002658A (es) | Una composicion farmaceutica para la estimulacion de la angiogenesis. | |
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
MY188825A (en) | High-concentration monoclonal antibody formulations | |
MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
WO2016042163A3 (en) | Ophthalmic drug compositions | |
EP2829265A3 (en) | Novel formulations for treatment of migraine | |
ES2362525B8 (es) | Formulación de medicamentos en forma de agujas percutaneas penetrantes. | |
IL294463A (en) | Methods for treating or preventing eye conditions | |
EA201891606A1 (ru) | Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона | |
WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
IN2014DN06920A (es) | ||
IN2015DN01349A (es) | ||
MD20140123A2 (ro) | Agenţi terapeutici optimizaţi pentru administrare subcutanată | |
WO2014183033A3 (en) | G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal | |
MX2017015293A (es) | Composicion para tratar lesiones tisulares. | |
MY191043A (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
NZ606236A (en) | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease | |
MX2017004378A (es) | Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea. | |
Paul-Visse et al. | Safety and efficacy of recombinant human platelet derived growth factor BB (rhPDGF-BB) in Parkinson’s disease | |
WO2014122638A3 (en) | Thalidomide and thalidomide analogues for the stimulation of stem cell factor | |
WO2016018454A3 (en) | Compositions and methods employing bcl2 and bcl2 family members | |
EA033539B1 (ru) | Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани при ее повреждении методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2 в ветеринарии и генетическая конструкция для реализации заявленного способа | |
Kottmann et al. | A60 LUNG FIBROSIS: ANIMAL MODELS I: The Lactate Dehydrogenase Inhibitor Gossypol Inhibits Bleomycin Induced Pulmonary Fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |